vs
AGENUS INC（AGEN）与RECURSION PHARMACEUTICALS, INC.（RXRX）财务数据对比。点击上方公司名可切换其他公司
RECURSION PHARMACEUTICALS, INC.的季度营收约是AGENUS INC的1.0倍（$35.5M vs $34.2M），AGENUS INC净利率更高（-31.0% vs -304.2%，领先273.2%），RECURSION PHARMACEUTICALS, INC.同比增速更快（681.7% vs 27.5%），过去两年RECURSION PHARMACEUTICALS, INC.的营收复合增速更高（60.5% vs 10.5%）
Agenus Inc.是一家总部位于美国马萨诸塞州列克星敦的生物技术公司，核心业务聚焦免疫治疗领域，尤其专注于利用人体免疫系统控制或治愈癌症的肿瘤免疫治疗。公司目前正在研发检查点调节剂、个性化抗癌疫苗，以及可适配多种疫苗的免疫佐剂，其中检查点调节剂作为当前进展迅速的方向，早期产品已为患者带来突破性临床获益。
Recursion Pharmaceuticals是一家临床阶段生物技术企业，依托人工智能技术和高通量生物实验体系，开发针对罕见病、肿瘤、炎症性疾病等领域未满足医疗需求的创新疗法，核心市场覆盖北美，与全球多家生物制药企业合作推进在研管线落地。
AGEN vs RXRX — 直观对比
营收规模更大
RXRX
是对方的1.0倍
$34.2M
营收增速更快
RXRX
高出654.3%
27.5%
净利率更高
AGEN
高出273.2%
-304.2%
两年增速更快
RXRX
近两年复合增速
10.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $34.2M | $35.5M |
| 净利润 | $-10.6M | $-108.1M |
| 毛利率 | — | 59.8% |
| 营业利润率 | 42.1% | -304.8% |
| 净利率 | -31.0% | -304.2% |
| 营收同比 | 27.5% | 681.7% |
| 净利润同比 | 77.3% | 39.6% |
| 每股收益（稀释后） | $0.09 | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AGENRXRX
| Q4 25 | $34.2M | $35.5M | ||
| Q3 25 | $30.2M | $5.2M | ||
| Q2 25 | $25.7M | $19.2M | ||
| Q1 25 | $24.1M | $14.7M | ||
| Q4 24 | $26.8M | $4.5M | ||
| Q3 24 | $25.1M | $26.1M | ||
| Q2 24 | $23.5M | $14.4M | ||
| Q1 24 | $28.0M | $13.8M |
净利润AGENRXRX
| Q4 25 | $-10.6M | $-108.1M | ||
| Q3 25 | $63.9M | $-162.3M | ||
| Q2 25 | $-30.0M | $-171.9M | ||
| Q1 25 | $-26.4M | $-202.5M | ||
| Q4 24 | $-46.8M | $-178.9M | ||
| Q3 24 | $-67.2M | $-95.8M | ||
| Q2 24 | $-54.8M | $-97.5M | ||
| Q1 24 | $-63.5M | $-91.4M |
毛利率AGENRXRX
| Q4 25 | — | 59.8% | ||
| Q3 25 | 97.9% | -183.8% | ||
| Q2 25 | 99.1% | -4.9% | ||
| Q1 25 | 99.4% | -48.0% | ||
| Q4 24 | 99.6% | -181.4% | ||
| Q3 24 | 99.4% | 53.7% | ||
| Q2 24 | 99.5% | 36.2% | ||
| Q1 24 | 99.6% | 19.1% |
营业利润率AGENRXRX
| Q4 25 | 42.1% | -304.8% | ||
| Q3 25 | -15.0% | -3327.6% | ||
| Q2 25 | -65.0% | -916.8% | ||
| Q1 25 | -55.3% | -1297.9% | ||
| Q4 24 | -96.5% | -4042.4% | ||
| Q3 24 | -125.5% | -377.1% | ||
| Q2 24 | -128.4% | -697.4% | ||
| Q1 24 | -117.4% | -698.4% |
净利率AGENRXRX
| Q4 25 | -31.0% | -304.2% | ||
| Q3 25 | 211.4% | -3135.3% | ||
| Q2 25 | -116.8% | -894.2% | ||
| Q1 25 | -109.6% | -1373.3% | ||
| Q4 24 | -174.4% | -3935.5% | ||
| Q3 24 | -267.7% | -367.5% | ||
| Q2 24 | -233.1% | -676.6% | ||
| Q1 24 | -226.6% | -662.4% |
每股收益（稀释后）AGENRXRX
| Q4 25 | $0.09 | $-0.17 | ||
| Q3 25 | $1.94 | $-0.36 | ||
| Q2 25 | $-1.00 | $-0.41 | ||
| Q1 25 | $-1.03 | $-0.50 | ||
| Q4 24 | $-1.95 | $-0.56 | ||
| Q3 24 | $-3.08 | $-0.34 | ||
| Q2 24 | $-2.52 | $-0.40 | ||
| Q1 24 | $-3.04 | $-0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $3.0M | $743.3M |
| 总债务越低越好 | $44.7M | $9.6M |
| 股东权益账面价值 | $-271.1M | $1.1B |
| 总资产 | $226.8M | $1.5B |
| 负债/权益比越低杠杆越低 | — | 0.01× |
8季度趋势，按日历期对齐
现金及短期投资AGENRXRX
| Q4 25 | $3.0M | $743.3M | ||
| Q3 25 | $3.5M | $659.8M | ||
| Q2 25 | $9.5M | $525.1M | ||
| Q1 25 | $18.5M | $500.5M | ||
| Q4 24 | $40.4M | $594.4M | ||
| Q3 24 | $44.8M | $427.6M | ||
| Q2 24 | $93.7M | $474.3M | ||
| Q1 24 | $52.9M | $296.3M |
总债务AGENRXRX
| Q4 25 | $44.7M | $9.6M | ||
| Q3 25 | $34.2M | $11.9M | ||
| Q2 25 | $33.9M | $14.2M | ||
| Q1 25 | $33.6M | $16.4M | ||
| Q4 24 | $33.2M | $19.0M | ||
| Q3 24 | — | $20.5M | ||
| Q2 24 | — | $22.9M | ||
| Q1 24 | — | — |
股东权益AGENRXRX
| Q4 25 | $-271.1M | $1.1B | ||
| Q3 25 | $-274.1M | $1.0B | ||
| Q2 25 | $-354.6M | $919.1M | ||
| Q1 25 | $-341.8M | $933.9M | ||
| Q4 24 | $-326.4M | $1.0B | ||
| Q3 24 | $-292.3M | $524.6M | ||
| Q2 24 | $-241.3M | $584.4M | ||
| Q1 24 | $-201.4M | $401.2M |
总资产AGENRXRX
| Q4 25 | $226.8M | $1.5B | ||
| Q3 25 | $233.9M | $1.4B | ||
| Q2 25 | $185.2M | $1.3B | ||
| Q1 25 | $200.2M | $1.3B | ||
| Q4 24 | $226.3M | $1.4B | ||
| Q3 24 | $238.5M | $726.5M | ||
| Q2 24 | $292.4M | $775.9M | ||
| Q1 24 | $256.6M | $557.8M |
负债/权益比AGENRXRX
| Q4 25 | — | 0.01× | ||
| Q3 25 | — | 0.01× | ||
| Q2 25 | — | 0.02× | ||
| Q1 25 | — | 0.02× | ||
| Q4 24 | — | 0.02× | ||
| Q3 24 | — | 0.04× | ||
| Q2 24 | — | 0.04× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-16.6M | $-46.1M |
| 自由现金流经营现金流 - 资本支出 | — | $-47.3M |
| 自由现金流率自由现金流/营收 | — | -133.1% |
| 资本支出强度资本支出/营收 | 0.0% | 3.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-378.3M |
8季度趋势，按日历期对齐
经营现金流AGENRXRX
| Q4 25 | $-16.6M | $-46.1M | ||
| Q3 25 | $-14.7M | $-117.4M | ||
| Q2 25 | $-20.2M | $-76.4M | ||
| Q1 25 | $-25.6M | $-132.0M | ||
| Q4 24 | $-28.7M | $-115.4M | ||
| Q3 24 | $-53.3M | $-59.2M | ||
| Q2 24 | $-38.2M | $-82.2M | ||
| Q1 24 | $-38.2M | $-102.3M |
自由现金流AGENRXRX
| Q4 25 | — | $-47.3M | ||
| Q3 25 | — | $-117.6M | ||
| Q2 25 | $-20.2M | $-79.6M | ||
| Q1 25 | $-25.6M | $-133.8M | ||
| Q4 24 | $-28.7M | $-116.7M | ||
| Q3 24 | $-53.3M | $-63.8M | ||
| Q2 24 | $-38.6M | $-83.4M | ||
| Q1 24 | $-38.2M | $-109.0M |
自由现金流率AGENRXRX
| Q4 25 | — | -133.1% | ||
| Q3 25 | — | -2272.5% | ||
| Q2 25 | -78.7% | -413.9% | ||
| Q1 25 | -106.5% | -907.4% | ||
| Q4 24 | -107.0% | -2567.7% | ||
| Q3 24 | -212.2% | -244.6% | ||
| Q2 24 | -164.4% | -578.5% | ||
| Q1 24 | -136.5% | -789.9% |
资本支出强度AGENRXRX
| Q4 25 | 0.0% | 3.5% | ||
| Q3 25 | 0.0% | 4.7% | ||
| Q2 25 | 0.0% | 16.4% | ||
| Q1 25 | 0.0% | 12.4% | ||
| Q4 24 | 0.3% | 28.6% | ||
| Q3 24 | 0.0% | 17.5% | ||
| Q2 24 | 2.0% | 8.2% | ||
| Q1 24 | 0.1% | 48.2% |
现金转化率AGENRXRX
| Q4 25 | — | — | ||
| Q3 25 | -0.23× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AGEN
| Non Cash Royalty Revenue | $31.1M | 91% |
| Other | $3.2M | 9% |
RXRX
暂无分部数据
